Sandoz has announced the appointment of Diane DiGangi Trench, as its UK Country Head.
Previously Vice-President, Market Access and Patient Services at Sandoz in the United States, Ms DiGangi Trench’s UK remit is to continue to expand access to biosimilar, generic and originator drugs to NHS patients. Her appointment coincides with the 15th anniversary of Sandoz launching the first biosimilar medicine approved for use in the UK.
Diane DiGangi Trench joined Sandoz in 2018. Her work in the US company elevated market access to become a strategic function and increased biosimilar adoption through building broader payer and stakeholder relationships. This year also marks 15 years of biosimilar medicines introducing pricing competition into the market, reducing the cost to the NHS and expanding the number of patients that can access biologic treatments. The National Institute for Health and Care Excellence (NICE) reviewing its appraisal method for biosimilar medicines is an opportunity to expand access to effective treatment with biosimilars in the UK.
Diane will be based in Sandoz’s Camberley HQ and will report to Christophe Delenta, Head of Cluster I, Sandoz Region Europe.
Commenting on her appointment, Ms DiGangi Trench said: “I am delighted to join the UK organisation as Country Head as we celebrate our 15 years in biosimilar medicines. Sandoz is a purpose-driven organisation and we are proud to support the NHS with our generic, biosimilar and originator medicines.”